Theranica develops wearable neuromodulation devices designed to provide drug-free relief from migraines. The company’s flagship product, Nerivio, is an FDA-cleared arm band controlled via smartphone that delivers targeted electrical stimulation to modulate pain pathways. Its approach focuses on non-invasive, at-home therapy that can both treat and prevent migraine attacks. Theranica positions its technology within regulated clinical care for migraine management.

The technology applies remote electrical pulses to the upper arm, engaging peripheral nerves to influence central pain-processing circuits. Smartphone control allows users to start, adjust, and track therapy sessions, while the device’s algorithms optimize stimulation parameters for effectiveness. The system is designed for ease of use, portability, and repeated home administration. This approach emphasizes safety, convenience, and adherence without requiring medication.

Theranica targets individuals suffering from episodic or chronic migraines seeking non-pharmacological management options. The Nerivio system is intended for use under physician guidance but is designed for self-administration at home. Its positioning reflects broader trends toward wearable, device-based therapies that provide accessible, evidence-based relief for neurological conditions.